Ethyl 7-hydroxy-7-phenylheptanoate

We are Ethyl 7-hydroxy-7-phenylheptanoate CAS:112665-42-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Ethyl 7-hydroxy-7-phenylheptanoate
CAS.NO:112665-42-6
Synonyms:Ethyl 7-hydroxy-7-phenylheptanoate
7-hydroxy-7-phenyl-heptanoic acid ethyl ester
 
Physical and Chemical Properties:
Molecular Formula C15H22O3
Molecular Weight 250.33300
 
Specification:
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Seratrodast(CAS:112665-43-7).

Ethyl 7-hydroxy-7-phenylheptanoate


Related News: The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.Cloruro de 2-oxo-1-imidazolidinacarbonilo CAS:13214-53-4 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.3-fluorobenzaldehído CAS:456-48-4 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.576-83-0 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.

Related Products
Product Name
Lanosterin View Details
[4-(pyrrolidin-1-ylsulfonylmethyl)phenyl]hydrazine,hydrochloride View Details
2-(tert-Butylamino)acetic acid hydrochloride View Details
1,6-Dichlorohexane manufacturer 4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine manufacturer 2-Fluoroisonicotinic Acid manufacturer 5-aza-2′-deoxycytidine manufacturer 4-Nitrophenyl isocyanate manufacturer